ଭେରିସିଗୁଆଟ

ଭେରିସିଗୁଆଟ
Clinical data
Trade names	Verquvo
AHFS/Drugs.com	monograph
data	US DailyMed: Vericiguat;
Pregnancy; category	AU: D ; Contraindicated;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate;
ECHA InfoCard	100.247.370
Chemical and physical data
Formula	C19H16F2N8O2
Molar mass	୪୨୬.୩୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N;
	InChI InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27); Key:QZFHIXARHDBPBY-UHFFFAOYSA-N;

ଭେରିସିଗୁଆଟ, ଅନ୍ୟ ବେପାର ନାମ ଭେର୍କୁଭୋ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଧୁନା ଖରାପ ଦିଗକୁ ଗତି କରୁଥିବା ହୃତ୍‌ପିଣ୍ଡ ସମ୍ପର୍କୀୟ ମୃତ୍ୟୁ ଓ ଡାକ୍ତରଖାନାରେ ଭର୍ତ୍ତି ହେବାର ଆଶଙ୍କା ହ୍ରାସ କରିବା ନିମନ୍ତେ ହୃଦଘାତରେ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୩] ^[୫] ଏହା କେବଳ ୪୫%ରୁ କମ୍ ଇଜେକସନ ଭଗ୍ନାଂଶ ଥିବା ଲୋକଙ୍କଠାରେ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତଚାପ ଏବଂ ନିମ୍ନ ଲୋହିତ ରକ୍ତ କଣିକା ଅନ୍ତର୍ଭୁକ୍ତ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ଦ୍ରବଣସମ୍ପନ୍ନ ଗୁଆନିଲେଟ୍ ସାଇକ୍ଲେଜ୍ (sGC) ଉତ୍ତେଜକ, ଏବଂ ଏହି ଶ୍ରେଣୀର ଅନ୍ୟ ଔଷଧ ସହିତ ବ୍ୟବହାର କରାଯିବା ଅନୁଚିତ ।^[୩] ^[୫]

୨୦୨୧ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଭେରିସିଗୁଆଟ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ମାସକୁ ଏହି ଔଷଧ ପିଛା ପ୍ରାୟ ୬୧୫ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୦୦ ପାଊଣ୍ଡ ।^[୭]

ସନ୍ଦର୍ଭ

↑ ^୧.୦ ^୧.୧ "Verquvo". Therapeutic Goods Administration (TGA). 29 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
↑ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Verquvo- vericiguat tablet, film coated". DailyMed. Archived from the original on 6 September 2021. Retrieved 9 February 2021.
↑ ^୪.୦ ^୪.୧ "Drug Trials Snapshot: Verquvo". U.S. Food and Drug Administration (FDA). 8 February 2021. Archived from the original on 9 February 2021. Retrieved 8 February 2021. This article incorporates text from this source, which is in the public domain.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Verquvo EPAR". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 15 September 2021. Retrieved 14 September 2021.
↑ "Verquvo". Archived from the original on 23 October 2022. Retrieved 23 October 2022.
↑ "Vericiguat". SPS - Specialist Pharmacy Service. 17 October 2016. Archived from the original on 3 March 2022. Retrieved 23 October 2022.

[Verquvo_APM_Summary-1] ୧.୦ ^୧.୧ "Verquvo". Therapeutic Goods Administration (TGA). 29 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.

[2] "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.

[PI2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Verquvo- vericiguat tablet, film coated". DailyMed. Archived from the original on 6 September 2021. Retrieved 9 February 2021.

[Snap2022-4] ୪.୦ ^୪.୧ "Drug Trials Snapshot: Verquvo". U.S. Food and Drug Administration (FDA). 8 February 2021. Archived from the original on 9 February 2021. Retrieved 8 February 2021. This article incorporates text from this source, which is in the public domain.

[EPAR2022-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Verquvo EPAR". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 15 September 2021. Retrieved 14 September 2021.

[6] "Verquvo". Archived from the original on 23 October 2022. Retrieved 23 October 2022.

[7] "Vericiguat". SPS - Specialist Pharmacy Service. 17 October 2016. Archived from the original on 3 March 2022. Retrieved 23 October 2022.

[୩]

[୫]

[୧]

[୨]

[୪]

[୬]

[୭]